Note: Descriptions are shown in the official language in which they were submitted.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
1
METHODS AND COMPOSITIONS FOR TREATING OXALATE-RELATED
CONDITIONS
Cross-reference to related applications
[01] This application is related to U.S. Provisional Application 61/281,907
filed November
25, 2009 and U.S. Provisional Application 61/395,929 filed May 20, 2010 to
which priority is
claimed under 35 USC 119.
Statement Regarding Federally Sponsored Development
[02] This invention was made with government support under Grant Number
1R43AT006065-01 awarded by the National Center for Complementary and
Alternative
Medicine (NCCAM), National Institute of Health (NIH). The Government has
certain rights
in the invention.
Background
[03] Approximately 3 million people visit health care providers each year for
kidney
stones. Of those 3 million patients, in the United States more than one half
million suffer
from kidney stone-related conditions. Kidney stones are a very common and
painful urinary
tract disorder. The most common type of stone contains calcium in combination
with either
oxalate or phosphate, in which approximately 70% is calcium oxalate.
(Tsujihata, M. (2008)
Mechanism of calcium oxalate renal stone formation and renal tubular cell
injury, Int J Urol
15, 115-120; Daudon, M., Dore, J. C., Jungers, P., and Lacour, B. (2004)
Changes in stone
composition according to age and gender of patients: a multivariate
epidemiological
approach, Urol Res 32, 241-247.) Many disease states are associated with an
excess quantity
of oxalate in the body including: primary hyperoxaluria, secondary
hyperoxaluria, autism,
vulvodynia, oxalosis associated with end-stage renal disease, cardiac
conductance disorders,
Crohn's disease, inflammatory bowel disease, colitis, urolithiasis, oxalosis
associated with
end-stage renal disease, sarcoidosis, asthma, COPD, fibromyalgia, Zellweger
syndrome,
bariatric surgery and other enteric disease states.
[04] Oxalate is normally produced in plants, and is primarily found in leaves,
nuts, fruits
and barks. In food products, oxalate is found in high levels particularly in
plant foods
including: vegetables, cereal grains, nuts, beans and beverages. A typical
daily intake of
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
2
oxalate is between 80-120 mg/day, but can range from 44-350 mg/day. Dietary
oxalate may
form sodium, potassium or calcium salts in food.
[05] Oxalate may be absorbed throughout the entire gastrointestinal tract (GI
tract)
including the stomach, and the small and large intestines. Therefore, removal
of dietary
oxalate in these organs is effective in preventing oxalate absorption.
Absorption of dietary
oxalate contributes to 10-70% of urinary oxalate secretion, likely a crucial
contribution to
urinary calcium oxalate supersaturation. (Holmes, R. P., Goodman, H. 0., and
Assimos, D.
G. (2001) Contribution of dietary oxalate to urinary oxalate excretion, Kidney
Int 59, 270-
276.) It is believed that calcium oxalate supersaturation is the determining
driving force of
calcium oxalate stone formation. Therefore, by reducing calcium oxalate
supersaturation, the
risk of stone formation will likely be significantly decreased.
[06] There are very few, if any, treatment strategies known to significantly
decrease the
risk of stone formation by reducing or eliminating the absorption of dietary
oxalate in the
system. One way to limit dietary oxalate absorption would be to orally
administer oxalate
degrading enzymes which come into contact with the stomach and the small and
large
intestines. The challenge in providing such treatment is the harsh acidic
stomach
environment, making it difficult for an enzyme to survive and function at a
low pH and in a
high pepsin activity environment. The small and large intestines also provide
a challenging
environment for the survival of an enzyme due to the high levels of trypsin
and chymotrypsin
activity. The pH in the stomach is affected by several factors including
individual stomach
health-related conditions, and quantity and substance of meals. These factors
may result in a
broad stomach pH range between 1.9-5.5. The pH in the human stomach is non-
homogenous
due to the presence of acid pockets. Hence, it is critical to find an oxalate-
degrading enzyme
that is stable and potent within this acidic pH range to be an effective
treatment for humans.
Additionally, the oxalate degrading enzyme must be stable within a pH range of
5.5-8.0 that
can withstand the conditions of the intestinal tract. The oxalate degrading
enzyme must be
protected from pepsin digestion in the stomach as well as from trypsin and
chymotrypsin in
the small and large intestines.
Summary
[07] The subject invention provides in one embodiment, an oxalate degrading
composition
including at least one oxalate degrading enzyme. The composition includes an
enriched
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
3
insoluble component of fungal biosample, and is effective to degrade oxalate
at a pH of 1.9 or
higher. The term "biosample" as used herein refers to a plurality of cells or
cell-containing
tissue(s) from a species of interest. In a typical embodiment, a biosample is
homogenized or
otherwise disrupted so as to break apart or lyse cells in the biosample. OxDC
and OxOx are
generally found in the insoluble component of cells, i.e. the proteins and
other structures (cell
wall/membranes) in cells that are not water-soluble. The insoluble component
of a biosample
can be enriched by removing at least a portion of the water and water-soluble
cellular
components from the water-insoluble components. Enrichment of the insoluble
component
can occur by means conventional in the art such as filtration, centrifugation,
lyophilization
and/or simple drying. In another embodiment, there is provided a method for
reducing the
amount of oxalate in a subject. The method includes administering a
therapeutically effective
amount of a composition including at least one oxalate degrading enzyme to the
subject. The
at least one oxalate degrading enzyme includes an enzyme that is active at a
pH level of 1.9-
6.3, such that the enzyme degrades soluble oxalate in the digestive tract of
the subject.
[08] In another embodiment, there is provided a method for preventing/treating
an oxalate-
related medical condition in a subject. The method includes administering a
therapeutically
effective amount of at least one oxalate degrading enzyme containing
composition to a
subject in need. The oxalate-related medical condition includes one of.
primary
hyperoxaluria, autism, secondary hyperoxaluria, Crohn's Disease, inflammatory
bowel
disease, colitis, cardiac conductance disorder, urolithiasis, vulvodynia,
bariatric surgery,
sarcoidosis, asthma, COPD, fibromyalgia, Zellweger syndrome, oxalosis
associated with end-
stage renal disease, and other enteric disease states.
[09] In a further embodiment, an article of manufacture including packaging
material and
an effective amount of oxalate degrading enzyme is provided. The packaging
material
includes at least one of. pills, candy, sachet, tablet, in bulk, bar, and/or a
food additive.
[010] In yet a further embodiment, a method for treating an oxalate-related
medical
condition is provided. The method includes coadministering to a subject in
need of such
treatment a therapeutically effective amount of a first composition, wherein
the first
composition releases enzymes in the stomach of the subject and a second
composition,
wherein the second composition releases enzymes in the intestinal tract of the
subject. The
method provides that when the enzymes are released, the first composition
degrades oxalate
in the stomach, and second composition degrades oxalate in the intestinal
tract.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
4
[011] In still a further embodiment, an oxalate degrading composition derived
from a fungal
source is provided. The composition includes at least a first composition and
a second
composition. The first composition includes at least one oxalate degrading
enzyme, wherein
the first composition releases the at least one oxalate degrading enzyme at a
pH within a pH
range of 1.9-6.3. The second composition includes at least one oxalate
degrading enzyme,
wherein said second composition releases the at least one oxalate degrading
enzyme at a pH
within a pH range of 5.5-8Ø
[012] In another embodiment, an article of manufacture comprising packaging
material and
an effective amount of oxalate degrading enzyme is provided. The article of
manufacture
includes a first composition, wherein the first composition is operable at a
pH within a first
pH range. The article of manufacture also includes a second composition,
wherein the
second composition is operable at a pH within a second pH range. The article
of manufacture
includes at least a first oxalate degrading enzyme and a second oxalate
degrading enzyme.
Brief Description of the Drawings
[013] Figure 1 shows a graph illustrating the pH activity profile of OxDC from
three fungi
species at pH 1.9-6.3.
[014] Figure 2 shows thermal stability of OxDc from three fungi species
[015] Figure 3 shows a graph illustrating the pH activity profile of OxOx from
Bougainvillea buganvilla at pH 5.0-8.5
[016] Figure 4 pH activity profile for OxDC from Boletus flaviporus, Coprinus
cometus,
and formulated OxDC from Coprinus cometus
[017] Figure 5 Soluble oxalate degradation with OxDC from Agrocybe aegerita in
3 food
mixture samples with pH values of 2.3, 3.4 and 5.2.
Detailed Description
[018] The invention is based on the inventors' pursuit of developing new
compositions for
degrading oxalate in a subject. OxDC activity has been evaluated in over one-
hundred
twenty different mushroom species entailed by this invention as provided in
Example 2.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
Many of them are edible or medicinally used mushrooms. OxDC activity from many
of these
mushroom fungi are stable and active from pH 1.9-2.5, 2.5-3.0, 3.0-3.5, 3.5-
4.0, 4.0-4.5, 4.5-
5.0, 5.0-5.5, 5.5-6.0 and 6.0-6.3, and protected from pepsin digestion.
Furthermore, some
strains of fungi are stable and show OxDC activity at temperatures exceeding
70 C. This
property is very helpful at predicting stability. Therefore, this present
invention comprises
these pH and thermally stable oxalate degrading enzymes.
[019] Accordingly, in one embodiment of the subject invention, there is
provided an oxalate
degrading composition including at least one oxalate degrading enzyme. The
composition
includes an enriched insoluble component of fungal biosample, and is effective
to degrade
oxalate at a pH of 1.9 or higher. Another aspect of the subject invention
provides a
composition in which at least one oxalate degrading enzyme includes an enzyme
that is
formulated and active at a pH within a pH range of 1.9-5.5, and/or a second
enzyme that is
active at a pH within a pH range of 5.0-8.0 or a combination of the first and
second enzymes.
In a more specific embodiment of the subject invention, a composition is
included in which
the enzyme comprises at least one of: oxalate-oxidase (OxOx), and/or oxalate
decarboxylase
(OXDC).
[020] Oxalate decarboxylase (OxDC) is an enzyme that degrades oxalate. OxDC
compositions disclosed herein typically come from edible or non-poisonous
fungi has ideal
properties to be a potential therapeutic or medical food or dietary supplement
or other
treatment strategy as they are stable and active at exemplary pH levels of 1.9-
2.5, 2.5-3.0,
3.0-3.5, 3.5-4.0, 4.0-4.5, 4.5-5.0, 5.0-5.5, 5.5-6Ø OxDC compositions of the
invention can
be intracellular or it may be membrane-bound or otherwise associated with the
cell wall. The
state of OxDC compositions from pepsin digestion, and is capable of degrading
the majority
of ingested oxalate in the stomach, the small intestines and the large
intestines. OxDC can be
prepared from mycelia of fungi grown by fermentation, or from fruit bodies or
mushrooms
formed by these fungi. These fungal mycelia or cleaned mushrooms or fruit
bodies
containing OxDC can be made into a solution, powder, or other formulation by
means of
grinding, mashing, suspending, mixing or other appropriate treatment as known
by those
skilled in the art. The mycelia, mushroom, or fruit body preparation can then
be dried and
formulated into tablets or capsules or packaged into sachets or made into bars
or made into
candy or incorporated into food compositions or other means of appropriate
distribution as
known by those skilled in the art. In one aspect, the oxalate degrading
composition of the
subject invention can be taken with meals and oxalate containing snacks. Such
a product has
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
6
a wide application within the calcium oxalate stone-forming population or
other conditions
related to oxalate in humans and non-humans. Such composition is in one
particular aspect
designed to degrade non-systemic oxalate, oxalate in the GI tract, notably in
the stomach, and
prevent exogenous oxalate (e.g. from food) from entering the systemic
circulation. In a more
specific embodiment, the enzyme is active and stable from pH 1.9-6
[021] According to an alternative embodiment, an oxalate degrading enzyme is
active at pH
of 3.0-6.5 when found associated to the cell wall but that is active from ph
3.0-7.0 when
purified and formulated into particles. According to another alternative
embodiment, oxalate
degrading enzyme containing composition includes a first enzyme stable and
active in the
stomach and a second enzyme stable in the stomach but only active in the
intestinal tract.
[022] Another class of oxalate degrading enzymes, oxalate-oxidase (OxOx), is
expressed in
higher plants and fungi and catalyzes the oxygen dependent oxidation of
oxalate to CO2 with
concomitant formation of H202. An aspect of the present invention relates to
the many
oxalate oxidase (OxOx) enzymes found in plants and fungi that are stable and
as described
above active at exemplary pH levels of 1.9-2.5, 2.5-3.0, 3.0-3.5, 3.5-4.0, 4.0-
4.5, 4.5-5.0 and
5.0-5.5. A particular OxOx enzyme from Bouganvillea buganvillea has been shown
to be
active from pH 5.5-8Ø
[023] These OxOx and OxDC enzymes can be prepared directly from these plants
or fungi
or from the genes encoding OxOx and OxDC, respectively, by cloning of these
genes, sub-
cloning into a recombinant expression system including, but not limited to, E.
coli, bacteria,
yeast, fungi and mammalian cells by using appropriate procedures commonly
accepted.
[024] After purified, the expressed OxOx enzyme can be formulated to resist
pepsin
digestion in the stomach and trypsin and chymotrypsin in the small and large
intestines by
various methods including, but not limited to, microencapsulation, attaching
to large
molecules such as PEG, or by modifying the molecular surface of the OxOx
enzyme. The
formulated enzyme can be made into, but are not limited to, a tablet, capsule,
sachets, candy,
bar, or incorporated into other food compositions or other formulations for
various modes of
distribution. Thus, the present invention relates to a composition, wherein
these oxalate-
degrading enzymes are embedded in a polymeric material, which protects the
enzymes from
degradation under gastric conditions. The fungal mycelia or cleaned mushrooms
or fruit
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
7
bodies or plant materials containing OxOx are made into a solution, powder, or
other physical
appearance by means of grinding, mashing, suspending, mixing or other
appropriate
treatment as known by those skilled in the art. The mycelia, mushroom, or
fruit body
preparation, or plant material is then dried and formulated into tablets or
capsules or
packaged into sachets or or made into bars or made into candy or incorporated
into other food
compositions or other means of appropriate distribution as known by those
skilled in the art.
[025] In another embodiment, an article of manufacture is provided, which
includes
packaging material and an effective amount of oxalate degrading enzyme. The
packaging
material comprises at least one of: pills, candy, sachet, tablet, in bulk,
bars, and/or a food
additive.
[026] In yet a further embodiment, an article of manufacture comprising
packaging material
and an effective amount of oxalate degrading enzyme is provided. The article
of manufacture
includes a first composition, wherein the first composition is operable at a
pH within a first
pH range, and a second composition, wherein the second composition is operable
at a pH
within a second pH range. The article of manufacture includes at least a first
oxalate
degrading enzyme and a second oxalate degrading enzyme. The first oxalate
degrading
enzyme may include a first component of an oral unit, and the second oxalate
degrading
enzyme may include a second component of an oral unit. The first component of
the oral unit
may surround the second component of the oral unit, or vice versa. The first
pH range
includes a pH of 1.9-5.5 and the second pH range includes a pH of 5.5-8Ø In
a specific
embodiment, the article of manufacture relates to a two-component pill or
tablet, wherein a
first component is contained within a second component. The term "oral unit"
as used herein
refers to an individual, predetermined dosage amount in a solid, semi-solid,
and/or liquid
form of a size and shape suitable for oral administration. Examples of oral
units include, but
are not limited to, capsules, tablets, pills, liquid suspensions, powders,
lozenge, etc. Also, an
oral unit can refer to a predetermined amount of a composition provided in an
ampoule or
packet, or other container that is opened to release its contents for oral
adminsitration.
[027] As used herein, the terms "subject" and "patient" are used
interchangeably. As used
herein, the term "subject" refers to an animal, preferably a mammal such as a
non-primate
(e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey
and human), and
most preferably a human.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
8
[028] In alternative embodiments, the present invention relates to OxDC that
can be
produced by recombinant expression. An aspect of the present invention relates
to the many
oxalate decarboxylase (OxDC) enzymes found in plants and fungi that are active
at
exemplary pH levels of 5.0-5.5, 5.5-6.0, and 6.0-6.5. Genes encoding OxDC from
these
fungi can be cloned and heterogeneously expressed in, but not limited to, E.
coli, bacteria,
yeast, fungi, or mammalian cells using appropriate procedures commonly
accepted by people
skilled in the art. Recombinant OxDC that is cloned, subcloned, and expressed
by, but not
limited to, E. coli, bacteria, yeast, fungi, or mammalian cells can be
purified by
chromatography methods and many other available methods that are well known by
people in
the field. The purified OxDC can be further formulated into a product to be
protected from
pepsin, trypsin and chymotrypsin digestion and achieve other beneficial
properties including
long shelf lifetime and a broader pH activity profile. Formulation can result
in the OxDC
enzyme being active from pH levels of 5.0-5.5, 5.5-6.0, 6.0-6.5, and 6.5-7Ø
[029] In another embodiment, the present invention relates to the second class
of oxalate
degrading enzymes, oxalate oxidase (E.C.1.2.3.4, OxOx), which is expressed in
higher order
plants. This enzyme catalyzes the oxygen dependent oxidation of oxalate to CO2
and
produces H202 during seed germination or during defense from parasite
invasions (40).
Some fungi have been reported to produce this enzyme as well (41). Indeed,
several fungi
tested under this invention show OxOx activity. OxOx from several plants and
fungi tested
under this invention, are stable and active at pH 1.9-5.5, and suitable to
degrade dietary
oxalate in the human stomach. Other OxOx enzymes from several plants and fungi
tested
under this invention, are active from pH 5.0-8.5, and suitable to degrade
dietary oxalate in the
non-human stomach, and small and large intestines.
[030] The present invention relates to the OxOx enzyme from plants and fungi
that can be
directly prepared from these organisms (40) (41) (42). Plants or fungi can be
grown under
conditions to achieve high OxOx content. The manufacturing process can be
similar to other
food production processes including, but not limited to, cleaning, sanitation,
milling, drying
and packaging.
[031] In an alternative embodiment, the present invention relates to the OxOx
enzyme that
can be produced through recombinant expression. Genes encoding OxOx from these
plants or
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
9
fungi can be cloned and heterogeneously expressed in, but not limited to, E.
coli, bacteria,
fungi or yeast (43, 44) and other kinds of plants (40, 45, 46). Plants
equipped with
recombinant OxOx can be used as raw materials in the similar manner as using
plants, which
express OxOx naturally. Recombinant OxOx expressed by, but not limited to, E.
coli,
bacteria, fungi or yeast or other appropriate system of expression can be
purified with
commonly accepted procedures and further formulated into a final product.
[032] In yet another embodiment, the present invention relates to the OxOx or
OxDC
enzyme dry powder or solution or other physical appearance that can be
manufactured into
various means of distribution including, but not limited to, tablets,
capsules, various kinds of
candy or bars, sachets, or directly as a powder.
[033] In another embodiment, a composition is provided in which the at least
one oxalate
degrading enzyme are derived from cell samples of the following: Dentinum
reparandum,
Russula virescens, Armillaria tabescens, Cantharellur cinnabarinur, Boletur
rubellus var
fraternus, Collybia acervata, Crepidotus mollis, Boletur subglabripes, Boletus
ornatipes,
Polyporus elegans, Pluteus cervinus, Sderoderma citrinum, Pleurotus ostreatus,
Xerula
radicata, Telephoro vlalis, Clitocybe, Cortinarius cedretorun, Lactarius
indigo, Russula
densifolia, Amanita rhopalopus, Clitocybe hydrograma, Amanita gemmata,
Cortinarius
lewisii, Pleurotus eryngii, Inocybe rimosa, Lactarius atrorividus, Russula
cyanoxhanth,
Sderoderma polyrhizum, Lentinula edodes, Hypsizygus tessellates, Flammulina
velutipes,
Leucangia carthusiana, Tuber oregonese, Grifola frondosa, Boletus
rubricitrinus, Boletus
fraternus, Gyroporus subalbellus, Leucoagaricus americanus, Omphalotus
olearius,
Coprinus disseminates, Amanita brunnescens, Russula helerophylla,
Mycorrhaphium
adustum, Armillaria tabescense, Boletus flaviporus, Russula pectintoides,
Lentinula boryana,
Amanita mutabilis, Gyroporus subalbellus 2nd, Collybia peronata, Lactarius
corrugis,
Rhodocybe, Macrocybe titaus, Collybia, Pluteus, Lactarius yazooensis, Leccinum
insigne,
Coprinus comatus, Polyporus tuberaster, Agrocybe aegerita, Trametes
versicolor,
Ganoderma lucidum, Hypsizygus ulmarius, Lentinula edodes (warm), Lentinula
edodes
(cold), Lentinula edodes (wide range), Russula amoenolens, Lactarius
tomentosu, and/or
Agaricus blazei. Optimum pH ranges of OxDC and/or OxOx from these select fungi
were
found between 1.9-6.3. Active pH ranges of OxDC and/or OxOx from these select
fungi
were found between 1.9-6.3, as noted in Table 1.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
Table 1. Optimum and Active pH Ranges of OxDC or OxOx from Select Fungi
Names Optimum pH range Active pH range
Dentinum repandum 1.9-3.2 1.9-4.3
Russula virescens 1.9-2.7 1.9-4.3
Boletur rubellus var aternus 1.9-3.2 1.9-4.3
Crepidotus mollis 3.2-4.3 1.9-5.3
Polyporus elegans 1.9-2.7 1.9-3.2
Scleroderma citrinum 1.9-3.2 1.9-5.3
Xerula radicata 2.7-3.2 1.9-5.3
Thelephora vlalis 1.9-2.7 1.9-4.8
Lactarius indigo 1.9-3.2 1.9-4.3
Russula densifolia 1.9-3.2 1.9-4.3
Pleurotus eryngii 3.5-4.5 3.2-5.3
Inocybe rimosa 2.7-3.2 1.9-4.8
Lactarius atrorividus 1.9-3.2 1.9-4.3
Scleroderma of rhizum 1.9-3.2 1.9-4.3
Lentinula edodes 2.5-3.0 1.9-5.5
Hypsizygus tessellatus 3.5-4.0 2.5-5.5
Hypsizygus tessellatus 3.5-4.0 2.5-5.5
Flammulina velutipes 2.7-4.0 1.9-5.5
Leucangia carthusiana 2.7-4.0 1.9-5.5
Tuber oregonense 2.7-4.0 1.9-5.5
Gri ola ondosa 2.7-3.2 1.9-3.2
Boletus rubricitrinus 1.9-2.7 1.9-3.2
Boletus fraternus 1.9-3.2 1.9-5.3
G ro orus subalbellus 1.9-3.2 1.9-5.3
Leucoagaricus americanus 1.9-3.2 1.9-4.3
Omphalotus olearius 1.9-4.3 1.9-5.3
Coprinus disseminates 2.7-3.2 1.9-4.3
Amanita brunnescens 2.7-3.2 1.9-4.3
Mycorrhaphium adustum 1.9-2.7 1.9-4.3
Armillaria tabescense 2.7-3.2 1.9-4.3
Boletus avi orus 2.7-5.3 1.9-6.3
Russula ectintoides 1.9-4.3 1.9-5.3
Amanita mutabilis 2.7-3.2 1.9-5.3
Gyroporus subalbellus 2" 1.9-3.2 1.9-5.3
Collybiaperonata 1.9-3.2 1.9-4.3
Rhodocybe 1.9-3.2 1.9-4.3
Macrocybe titaus 2.7-3.2 1.9-4.3
Lactarius yazooensis 2.7-4.3 1.9-5.3
Leccinum insigne 2.7-3.2 1.9-4.8
Coprinus comatus 3.2-6.0 1.9-6.3
Polyporus tuberaster 1.9-3.2 1.9-4.8
Agrocybe aegerita 2.7-3.7 1.9-6.3
Trametes versicolor 1.9-2.3 1.9-4.3
Ganoderma lucidum 1.9-2.7 1.9-4.5
H si us ulmarius 3.0-4.0 1.9-6.3
Lentinula edodes (warm) 2.5-3.0 1.9-5.5
Lentinula edodes (cold) 2.5-3.0 1.9-5.5
Lentinula edodes (wide range) 2.5-3.0 1.9-5.5
A aricus blazei (OxOx) 2.5-3.0 1.9-4.8
Lactarius tomentosu (OxOx) 2.5-3.0 1.9-4.3
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
11
[034] In a more specific embodiment, the invention relates to OxDC and/or OxOx
from
these fungi that can be directly made from mycelia. Mycelia can be produced by
fermentation technology. Fermentation processes for growing fungi is well
developed and
known by people skilled in the art. The fermentation process development
includes medium
optimization and fermentation process control parameters, optimization to
achieve optimum
fungal growth, and an induction method optimization to achieve maximum OxDC
and/or
OxOx production. The medium optimization, fermentation process optimization,
and
induction process optimization may vary with specific fungal species. It is
well known by
people in the field, that different fungi may require different medium
compositions,
temperature, and pH to grow, and require different induction conditions to
produce OxDC
and/or OxOx, such as pH range. OxDC and/or OxOx produced from these mycelia
can be
presented as, but not limited to, dry powder, solutions or other physical
appearance by means
of grinding, mashing, suspending, mixing or other appropriate treatment. After
harvesting,
these mycelia can be dried and milled into powder or other physical
appearance.
[035] In a more particular embodiment, a composition is provided where the at
least one
oxalate degrading enzyme is obtained from two or more of: Flammulina
velutipes, Agrocybe
aegerita, and Coprinus comatus, or any combination thereof, wherein the
composition is
active at a pH of 1.9-6.3.
[036] In an alternative embodiment, a method for reducing the amount of
oxalate in a
subject is provided. The method includes administering a therapeutically
effective amount of
a composition including at least one oxalate degrading enzyme to the subject.
The at least
one oxalate degrading enzyme includes an composition that is active at a pH
level of 1.9-6.3,
wherein the enzyme degrades soluble oxalate in the digestive tract of the
subject. In a more
particular embodiment, the therapeutically effective amount of the composition
is orally
administered to the subject. In a further embodiment, the at least one oxalate
degrading
enzyme comprises at least one of. oxalate-oxidase (OxOx), and/or oxalate
decarboxylase
(OxDC).
[037] According to other embodiments, the present invention comprises methods
to
administer compositions comprising oxalate degrading enzymes to the stomach
and later the
small and large intestines, and such compositions are useful for degrading
dietary oxalate as
well as systemic oxalate and aiding in preventing the uptake of oxalate from
the stomach and
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
12
intestinal tract, which provides methods for treatment and prevention of
oxalate-related
diseases and disorders, such as, e.g., hyperoxaluria, primary hyperoxaluria,
idiopathic
calcium oxalate kidney stone disease (urothiliasis), and absorptive and
enteric hyperoxaluria.
The compositions comprise polymeric or copolymeric materials so that the
administered
enzymes are protected from the protein degradation and/or pH or acidic
dependent
degradation occurring under gastric conditions of the stomach, i.e. low pH and
the presence
and activity of pepsin as well as trypsin and chymotrypsin within the small
and large
intestines.
[038] In specific embodiments, the present invention comprises compositions,
wherein the
oxalate reducing enzymes are combined in a polymeric material, which protects
the enzymes
from degradation under gastric conditions and/or also under intestinal
conditions. It can be
envisaged that this composition may comprise any enzymes or cofactors, and the
present
invention contemplates compositions that comprise oxalate degrading enzymes,
such as,
oxalate decarboxylase, oxalate oxidase, or a combination of oxalyl-CoA
decarboxylase and
formyl CoA transferase, or a combination of any of these.
[039] Since there is evidence indicating that absorption of dietary oxalate
has a significant
contribution to urinary calcium oxalate supersaturation, any treatment
strategy that
significantly reduces the absorption of dietary oxalate in stone formers is
likely to decrease
the risk of stone formation. Clinical trials with calcium supplemented diets,
to bind oxalate
and thus limit oxalate absorption, have showed a reduction in the absorption
of dietary
oxalate (13). However, this likely results in more calcium absorption from the
diet and thus
an increased risk of stone formation in certain individuals (14). The
inventors have
discovered that embodiments of the invention possess the ability to avoid
modifying urinary
chemistry parameters such as pH or calcium concentration; thereby, reducing
risks of uric
acid or phosphate stone formation (15).
[040] O. formigenes, an anaerobic organism that colonizes the large intestine
of animals and
humans and uses oxalate as its sole energy source, has been evaluated as a
therapeutic to treat
primary hyperoxaluria (16). However, the mode of action of O. formigenes
prevents it from
acting as a dietary oxalate intercept. Therefore, OxDC from Bacillus subtilis
was evaluated to
reduce dietary oxalate. Reduction of dietary oxalate absorption by using this
enzyme has been
tested in mice, rats and healthy human volunteers (17). Urinary oxalate from
both mice and
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
13
rats was significantly lower (-50%) than controls, but there was no
significant urinary oxalate
reduction in a double-blind placebo-controlled healthy human volunteer dose
escalation study
(18, 19). A likely explanation, is that the enzyme is inactivated in the human
stomach due to
the acidic environment of the stomach. This argument is supported by the fact
that the fasted
rat stomach is -pH 4.0 (20), while the fasted human stomach is -pH 1.5 (21).
[041] After meal consumption, the human stomach pH increases to a broad pH
range of 2.0-
5.5, which varies with meal contents and amounts, individual stomach
conditions, and the
amounts of stomach juice in the stomach. Further, its widely regarded that the
pH is non-
homogenous due to acid pockets (21), meaning the pH in places close to acid
pockets may be
far lower than the average pH of the stomach. OxDC from Bacillus subtilis
loses its activity
in less than one minute when exposed to a pH 3.0 or lower.
[042] Therefore, to be an effective treatment for humans or non-humans it is
crucial for
oxalate-degrading enzymes to be stable, pepsin resistant, trypsin resistant,
and/or
chymotrypsin resistant and active, degrade most available (5-10, 10-20, 20-30,
30-40, 40-50,
50-60, 60-70, 70-80, 80-90, or 90-100%) ingested oxalate in the stomach within
the gastric
emptying time, at this acidic pH range of 1.9-2.5, 2.5-3.0, 3.0-3.5, 3.5-4.0,
4.0-4.5, 4.5-5.0,
5.0-5.5, 5.5-6.0 and 6.0-6.3 to cover the majority of situations that are
likely to occur in the
human or non-human stomach and duodenum to be an effective treatment for
humans and
non-humans. Furthermore, at low pH, more oxalate is soluble and available for
absorption.
Thus, an enzyme, which is stable, protease (pepsin, trypsin, chymotrypsin etc)
resistant, and
active at low pH is crucial to be able to reduce soluble oxalate in the
stomach and duodenum
acidic environments of humans and non-humans and hence decrease oxalate
absorption.
[043] According to other embodiments, the present invention comprises
compositions of the
two classes of oxalate-degrading enzymes that may be stable and active from pH
2.0-5.5
and/or pH 5.0-8.5, oxalate decarboxylase and oxalate oxidase (22). Oxalate
decarboxylase
(EC 4.1.1.2), requires a catalytic amount of oxygen to convert oxalate to
formate and carbon
dioxide and is widely distributed in bacteria and fungi. OxDC from B. subtilis
is the most
studied bacterial OxDC (23). The enzyme is encoded by the YvrK gene in B.
subtilis. The
gene was cloned and expressed in E. coli, and was demonstrated to be potent at
degrading
oxalate (23). Recombinant OxDC has been well characterized by biophysical and
biochemical analysis as well as x-ray crystallography (24, 25). However, this
specific OxDC
is unstable at pH below 3.2, making it difficult to remain folded and capable
to degrade
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
14
dietary oxalate within the human stomach. Studies of bacterial oxalate
decarboxylase at
enzymology level are largely limited to the YvrK gene product, but a search of
Pubmed with
the term "oxalate decarboxylase" revealed 490 entities from bacteria and 172
entries from
fungi as of November 8, 2010, indicating an abundance of genes encoding OxDC
or putative
OxDC throughout bacteria. OxDC is widely distributed in the fungal kingdom as
well. From
the hundred and twenty or more fungal species tested in this invention, the
majority were
found to contain oxalate-degrading activity (specifically OxDC activity). Even
for those,
which did not show OxDC activity as evaluated under the tests outlined in this
invention,
they may contain oxalate-degrading activity as well, if considering that their
oxalate-
degrading activity might be lost during the material production or storage, or
if the oxalate-
degrading enzymes are only expressed under certain phases of its life cycle.
This observation
is further supported by literature that a search of Pubmed with the term
"oxalate
decarboxylase" revealed 172 entities from fungi as of November 8, 2010,
further indicating
that OxDC is a common enzyme in the fungal kingdom. Some of the OxDC enzymes
and the
products of these genes may be stable and active in the pH range of 1.9-2.5,
2.5-3.0, 3.0-3.5,
3.5-4.0, 4.0-4.5, 4.5-5.0 and 5.0-5.5, or be stable and active in the pH range
of 5.0-5.5, 5.5-
6.0, 6.0-6.5, 6.5-7.0, 7.0-7.5, and 7.5-8Ø Therefore, this present invention
comprises
compositions containing such stable oxalate degrading enzymes.
Determination of a Therapeutically Effective Dose
[044] An oxalate-degrading composition embodiment of the invention is
administered in a
desired amount, such as an amount that is sufficient to degrade substantially
all oxalate
normally present in a standard meal. Depending on the food choices, an average
Western
diet can contain 100 to 300 mg of oxalate/day.
[045] A therapeutically effective amount may comprise an amount of activity
units of
oxalate-reducing enzyme activity that will reduce a portion of the oxalate
present, or a level
of activity units of oxalate-reducing enzyme activity that will initiate a
reduction in the
amount of oxalate or maintain a lowered amount of oxalate in the individual,
compared to the
amount of oxalate present before administration of the composition. The number
of activity
units of oxalate-reducing enzyme activity that can be used in a single dose
composition can
range from about 0.0001 units to about 10,000 units, from about 5 units to 100
units, from
0.05 to 50 units, to 0.5 to 500, from about 0.01 units to about 50 units, from
about 0.01 units
to about 5 units, from about 1 units to about 100 units, from about 25 units
to about 50 units,
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
from about 30 units to about 100 units, from about 40 units to about 120
units, from about 60
units to about 15, from about 50 units to about 100 units, from about 100
units to about 500
units, from about 100 units to about 300 units, from about 100 units to about
400 units, from
about 100 units to about 10,000 units, from about 1,000 units to about 5,000
units, from about
2,500 units to about 10,000 units, from about 0.001 units to about 2,000 units
and all ranges
encompassed therein. A unit of the enzyme is the amount of enzyme that will
degrade one
micromole of oxalate per minute at 37 C. Also, the unit ranges above relate to
the number of
units per gram of composition.
[046] Additionally, a composition according to the present invention may
comprise
enzymes that comprises modifications or mutations, including, but not limited
to, chimeras
formed using domains comprising the oxalate degrading active site of an
oxalate reducing
enzyme, or peptide fragments notably those comprising of the active sites;
modifications or
mutations, including but not limited to, deletions, insertions, replacements,
reversions,
mutations for increased activity, substitution of naturally occurring amino
acids with non-
natural amino acids, or other modifications known to those skilled in the art.
[047] Compositions which exhibit large therapeutic indices are generally
desired. The data
obtained from cell culture assays and animal studies are used in formulating a
range of
dosage for human use. The dosage contained in such compositions is preferably
within a
range of circulating concentrations that include the ED50 with little or no
toxicity. The dosage
varies within this range depending upon the dosage form employed, sensitivity
of the patient,
and the route of administration.
[048] The exact dosages used in method embodiments can be adjusted, in light
of factors
related to the subject that requires treatment, to provide sufficient levels
of the active
ingredient or to maintain the desired effect. Factors which can be taken into
account include
the severity of the disease state, general health of the subject, age, weight,
and gender of the
subject, diet, time and frequency of administration, drug combination(s),
reaction
sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical
compositions can
be administered every 3 to 4 days, every week, or once every two weeks
depending on the
half-life and clearance rate of the particular formulation.
[049] In certain embodiments, normal dosage amounts can vary from 0.1 to
100,000
micrograms, up to a total dose of about 50 g, depending upon the route of
administration.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
16
Guidance as to particular dosages and methods of delivery is provided in the
literature and
generally available to practitioners in the art. Those skilled in the art will
employ different
formulations for nucleotides than for proteins or their inhibitors. Similarly,
delivery of
polynucleotides or polypeptides will be specific to particular cells,
conditions, locations, etc.
Compositions and Administration
[050] The invention provides compositions which can be administered to a
patient to
achieve a therapeutic effect. Compositions of the invention can comprise, for
example,
oxalate-oxidase (OxOx), and/or oxalate decarboxylase (OxDC). The compositions
can be
administered alone or in combination with at least one other agent, such as
stabilizing
compound, which can be administered in any sterile, biocompatible
pharmaceutical carrier,
including, but not limited to, saline, buffered saline, dextrose, and water.
The compositions
can be administered to a patient alone, or in combination with other agents,
drugs or
hormones. As noted above, composition embodiments may comprise polymeric or
copolymeric materials so that the administered enzymes are further protected
from the protein
degradation and/or pH or acidic dependent degradation occurring under gastric
conditions of
the stomach, i.e. low pH and the presence and activity of pepsin.
[051] In addition to the active ingredients, these pharmaceutical compositions
can contain
suitable pharmaceutically acceptable carriers comprising excipients and
auxiliaries which
facilitate processing of the active compounds into preparations which can be
used
pharmaceutically. Compositions of the invention are typically administered via
oral
administration, but it is conceived that other routes of administration might
be developed as
well, including, but not limited to, intravenous, intramuscular, intra-
arterial, intramedullary,
intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal,
intranasal, parenteral,
topical, sublingual, or rectal means. Compositions designed for oral
administration can be
formulated using pharmaceutically acceptable carriers well known in the art in
dosages
suitable for oral administration. Such carriers enable the pharmaceutical
compositions to be
formulated as tablets, pills, dragees, capsules, liquids, gels, syrups,
slurries, suspensions, and
the like, for ingestion by the patient.
[052] Compositions for oral use can be obtained through combination of active
compounds
with solid excipient, optionally grinding a resulting mixture, and processing
the mixture of
granules, after adding suitable auxiliaries, if desired, to obtain tablets or
dragee cores.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
17
Suitable excipients are carbohydrate or protein fillers, such as sugars,
including lactose,
sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or
other plants; cellulose,
such as methyl cellulose, hydroxypropylmethylcellulose, or sodium
carboxymethylcellulose;
gums including arabic and tragacanth; and proteins such as gelatin and
collagen. If desired,
disintegrating or solubilizing agents can be added, such as the cross-linked
polyvinyl
pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
[053] Dragee cores can be used in conjunction with suitable coatings, such as
concentrated
sugar solutions, which also can contain gum arabic, talc,
polyvinylpyrrolidone, carbopol gel,
polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable
organic solvents
or solvent mixtures. Dyestuffs or pigments can be added to the tablets or
dragee coatings for
product identification or to characterize the quantity of active compound,
i.e., dosage.
[054] Preparations which can be used orally include push fit capsules made of
gelatin, as
well as soft, sealed capsules made of gelatin and a coating, such as glycerol
or sorbitol. Push
fit capsules can contain active ingredients mixed with a filler or binders,
such as lactose or
starches, lubricants, such as talc or magnesium stearate, and, optionally,
stabilizers or maybe
by themselves. In soft capsules, the active compounds can be dissolved or
suspended in
suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol
with or without
stabilizers.
[055] Pharmaceutical formulations suitable for parenteral administration can
be formulated
in aqueous solutions, preferably in physiologically compatible buffers such as
Hanks'
solution, Ringer's solution, or physiologically buffered saline. Aqueous
injection suspensions
can contain substances which increase the viscosity of the suspension, such as
sodium
carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of
the active
compounds can be prepared as appropriate oily injection suspensions. Suitable
lipophilic
solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty
acid esters, such as
ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino
polymers also can be
used for delivery. Optionally, the suspension also can contain suitable
stabilizers or agents
which increase the solubility of the compounds to allow for the preparation of
highly
concentrated solutions. For topical or nasal administration, penetrants
appropriate to the
particular barrier to be permeated are used in the formulation. Such
penetrants are generally
known in the art.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
18
[056] Pharmaceutical preparations using oxalate degrading enzyme compositions
contemplated herein can be manufactured in a manner that is known in the art,
e.g., by means
of conventional mixing, dissolving, granulating, dragee making, levigating,
emulsifying,
encapsulating, entrapping, or lyophilizing processes. The pharmaceutical
composition can be
provided as a salt and can be formed with many acids, including but not
limited to,
hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts
tend to be more
soluble in aqueous or other protonic solvents than are the corresponding free
base forms. In
other cases, the preferred preparation can be a lyophilized powder which can
contain any or
all of the following: 150 mM histidine, 0.1 %2% sucrose, and 27% mannitol,
that is combined
with buffer prior to use.
[057] Further details on techniques for formulation and administration can be
found in the
latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (Maack Publishing Co.,
Easton, Pa.). After pharmaceutical compositions have been prepared, they can
be placed in an
appropriate container and labeled for treatment of an indicated condition.
Such labeling
would include amount, frequency, and method of administration.
[058] In any of the embodiments described above, any of the compositions of
the invention
can be administered in combination with other appropriate therapeutic agents.
Selection of
the appropriate agents for use in combination therapy can be made by one of
ordinary skill in
the art, according to conventional pharmaceutical principles. The combination
of therapeutic
agents can act synergistically to effect the treatment or prevention of the
various disorders
described above. Using this approach, one may be able to achieve therapeutic
efficacy with
lower dosages of each agent, thus reducing the potential for adverse side
effects.
[059] Any of the therapeutic methods described above can be applied to any
subject in need
of such therapy, including, for example, mammals such as dogs, cats, cows,
horses, rabbits,
monkeys, and most preferably, humans.
[060] In a particular embodiment, the enzyme is oxalate-oxidase. In a further
embodiment,
the enzyme is isolated from a fungal source. In another embodiment, the enzyme
is oxalate
decarboxylase. In a further embodiment, the enzyme is isolated from a fungal
or bacterial
source. In a particular embodiment, the at least one oxalate degrading enzyme
comprises an
enzyme that is active at a pH of 1.9-6.3. In another embodiment, the at least
one oxalate
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
19
degrading enzyme comprises an enzyme that is active at a pH of 5.8-8. In a
particular
embodiment, the at least one oxalate degrading enzyme is obtained from one of.
Flammulina
velutipes, Agrocybe aegerita, or Coprinus comatus, or any combination thereof,
wherein said
enzyme is active at a pH of 1.9-6.3.
[061] In another embodiment is provided a method for treating an oxalate-
related medical
condition in a subject. The method comprises administering a therapeutically
effective
amount of at least one oxalate degrading enzyme containing composition to a
subject in need.
The oxalate-related medical condition includes but is not limited to one of:
primary
hyperoxaluria, autism, secondary hyperoxaluria, Crohn's Disease, inflammatory
bowel
disease, colitis, cardiac conductance disorder, urolithiasis, vulvodynia,
oxalosis associated
with end-stage renal disease, bariatric surgery, and other enteric disease
states. In a further
embodiment, the at least one oxalate degrading enzyme comprises an enzyme that
is active at
a pH of 1.9-6.3. In an alternate embodiment the at least one oxalate degrading
enzyme
comprises an enzyme that is active at a pH of 5.5-8Ø
[062] If the enzyme is active around neutral pH of 5.5-8.0, but is not stable
at acid pH, the
enzyme containing compositions or formulated enzyme can be incorporated into a
capsule or
tablet and the capsule or tablet can be further coated with acid protection
film/membrane to
aid the capsule or tablet to pass through the stomach. When the capsule or
tablet reaches the
small intestine or large intestine, where the pH is 6.5-7.5, much higher than
the stomach, the
coated film/membrane will dissolve/break to release the enzyme containing
compositions or
formulated enzyme. The enzyme will degrade oxalate in the small and/or large
intestines.
This technology is well known for those who are skilled in the art.
[063] In another embodiment the at least one oxalate degrading enzyme
comprises at least
one of. oxalate-oxidase (OxOx), and/or oxalate decarboxylase (OxDC). In a
further
embodiment, the at least one oxalate degrading enzyme is obtained from one of.
Flammulina
velutipes, Agrocybe aegerita, or Coprinus comatus, or any combination thereof,
wherein said
enzyme is active at a pH of 1.9-6.3.
[064] In another embodiment, the patient in need is determined by the
conditions the patient
exhibits. As aforementioned, the exact dosage will be determined by the
practitioner, in light
of factors related to the subject that requires treatment. Dosage and
administration are
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
adjusted to provide sufficient levels of the active ingredient or to maintain
the desired effect.
Factors which can be taken into account include the severity of the disease
state, general
health of the subject, age, weight, and gender of the subject, diet, time and
frequency of
administration, drug combination(s), reaction sensitivities, and
tolerance/response to therapy.
Long-acting pharmaceutical compositions can be administered every 3 to 4 days,
every week,
or once every two weeks depending on the half-life and clearance rate of the
particular
formulation.
[065] In a more particular embodiment, the administration step is by oral
administration.
Compositions for oral administration can be formulated using pharmaceutically
acceptable
carriers well known in the art in dosages suitable for oral administration.
Such carriers enable
the pharmaceutical compositions to be formulated as tablets, pills, dragees,
capsules, liquids,
gels, syrups, slurries, suspensions, and the like, for ingestion by the
patient.
[066] In another embodiment of the present invention, a method for treating an
oxalate-
related medical condition is provided. The method includes coadministering to
a subject in
need of such treatment a therapeutically effective amount of a first
composition, wherein the
first composition releases enzymes in the stomach of the subject, and a second
composition,
wherein the second composition releases enzymes in the intestinal tract of the
subject. When
the enzymes are released, the first composition degrades oxalate in the
stomach, and the
second composition degrades oxalate in the intestinal tract. The method is
provided wherein
the coadministration can be either sequential or simultaneous. The first and
second
compositions may be administered by the same or by different mode of delivery.
The first
and second compositions may include at least one of OxOx or and OxDC,
respectively, or
OxDC and OxOx, respectively.
[067] There is provided in a further embodiment, an oxalate degrading
composition derived
from a fungal source. The composition includes at least a first powder and a
second powder.
The first powder includes at least one oxalate degrading enzyme, wherein the
first powder
releases the at least one oxalate degrading enzyme at a pH within a pH range
of 1.9-5.5. The
second powder comprising at least one oxalate degrading enzyme, wherein the
second
powder releases the at least one oxalate degrading enzyme at a pH within a pH
range of 5.5-
8Ø The oxalate degrading enzyme may be associated with a polymer, and may
comprise
OxOx and/or OxDC.
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
21
[068] All patents, patent applications and references included herein are
specifically
incorporated by reference in their entireties. It should be understood, of
course, that the
foregoing relates only to exemplary embodiments of the present invention and
that numerous
modifications or alterations may be made therein without departing from the
spirit and the
scope of the invention as set forth in this disclosure. Although the exemplary
embodiments of
the present invention are provided herein, the present invention is not
limited to these
embodiments. There are numerous modifications or alterations that may suggest
themselves
to those skilled in the art.
[069] The present invention is further illustrated by way of the examples
contained herein,
which are provided for clarity of understanding. The exemplary embodiments
should not to
be construed in any way as imposing limitations upon the scope thereof. On the
contrary, it
is to be clearly understood that resort may be had to various other
embodiments,
modifications, and equivalents thereof which, after reading the description
herein, may
suggest themselves to those skilled in the art without departing from the
spirit of the present
invention and/or the scope of the appended claims.
Formulation:
[070] Microencapsulation is widely applied for controlled release, or enteric
coating for
modification of food or drug flavor/taste, or protection of the drug component
from acid or
enzyme inactivation (71-73). There are many different physical and chemical
approaches to
prepare microencapsulation. Spray drying and lyphilization are two approaches
that have a
long existing industrial process with rich experience (74). The process is
relatively simple for
scaling up and relatively inexpensive.
[071] There are many natural and synthetic polymers for microencapsulation
selection
development including chitosan, gelatin, alginate, pectin, and the Eudragit
polymer series
such as L-100-55 (71-73). The keys for selecting polymers are their
compatibility with the
enzyme and the solubility in the GI tract. For example, the selected polymer
should not
reduce the stability of the enzymes. Since the formulated enzymes are expected
to work
throughout the entire GI tract, the microencapsulated enzyme particles should
stay intact
throughout the GI tract, but also should have hydrophilic pores for water and
oxalate
movement. To maintain particle formation, the selected polymer can either be
insoluble at pH
2-8, but form small hydrophilic pores for oxalate and water movement, or the
polymer can be
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
22
soluble, but cross-linked by a chemical method or a physical method that make
the water
soluble polymer insoluble.
[072] Chitosan has been successfully used to prepare microencapsulated
particles by spray
drying (75, 76) and it contains large numbers of free amino groups for
chemical cross-linking
by several cross-linkers including genipin (77-79). In our primary data,
chitosan has been
shown to extend the upper activity limit from pH 6.5 to pH 7.0 of the OxDC
from Coprinus
Cometus, which allows the enzyme to be active in most segments of the GI
tract. By
controlling manufacturing conditions and raw materials, chitosan can be
produced in a broad
range of molecular weights and various degrees of deacetylation to fit
different application
purposes (80, 81). Molecular weight and degree of deacetylation significantly
affect
chitosan/water interactions. Chitosan usually dissolves in water at acidic pH
(pH<4), but its
solubility in water is affected by its molecular size and degree of
deacetylation, where small
molecular weight and high degree of deacetylation make the polymer more
soluble in
relatively high pH (for example, pH <5), but larger molecules of chitosan with
relative low
degree of deacetylation only dissolve at very acid pH (for example, pH <3).
Molecular
weight and degree of deacetylation of chitosan also significantly affect
chitosan/enzyme
interactions. Larger molecules of chitosan with relative low degree of
deacetylation may
microencapsulate enzymes more efficiently due to its hydrophobic interactions
between
enzyme and chitosan molecules. For example, two OxDC enzymes from Boletus
Flaviporus
and Coprinus Cometus are both stable at very acidic pH (pH 2-3), which makes
it possible to
use large chitosan molecules with relative low degrees of deacetylation. These
chitosan
molecules can slowly dissolve at a very low pH (for example, pH 2.2) during
formulation, but
may not dissolve even in the stomach once formulated as particles. Thus, cross-
linking may
not be required and a small ratio of chitosan:enzyme may be achievable, which
may yield
highly active products due to a low ratio of excipient:enzyme and no activity
losses due to
chemical cross-linking.
[073] Gelatin or plant source proteins as representatives of protein polymers
are also
common formulation components. The solubility of protein microencapsulated
particles in
water can be reduced by a suitable chemical cross-linker such as genipin (82,
83).
[074] Alginate and pectin, similar to each other, are representatives of the
polymers
containing rich carboxyl groups, which can dissolve in water at neutral or
alkaline pH. The
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
23
formulated particles will dissolve in water as well, but the solubility of the
formulated
particles could be limited by cross-linking with Ca 2+ or genipin (82, 83).
[075] The polymers from the Eudragit polymer series, for enteric coating or
sustained
release formulations, are good candidates for protecting the enzymes from
protease digestion
and can be easily incorporated into the spray drying process (84). These
polymers either are
insoluble or soluble at high pH (5.5-7.0) and no cross-linking is required.
[076] Spray drying conditions may change with polymer selection, compositions,
and
requirements of spray drying products. Therefore, spray drying under several
different
conditions to achieve microencapsulation will need to be evaluated (74).
[077] The Eudragit polymer series for enteric coating or sustained release
formulations are
good candidates for protecting enzymes from protease digestion. Enzymes may be
mixed
with these polymers at a series of ratios, and certain excipients may be
incorporated to protect
the enzymes from the spray drying process, provide long term storage
properties, and/or
modify the properties of the final particles such as water and oxalate
permeability.
EXAMPLES
Example 1: Assays
[078] Activity assay: Liquid samples including supernatant, extraction and
enzyme solutions
were directly assayed for activity, whereas solid samples including pellet and
dry powder
were assayed after re-suspension with DI water. Fourty microliters of liquid
sample or solid
sample suspension was incubated with 360 l of 2 mM oxalate in 50 mM citrate
buffer, pH
3.5, at 37 C for 10-60 min. The reaction was quenched by the addition of 100
L 0.5 N
NaOH. The reaction mixture was immediately centrifuged. The supernatant is
diluted 10
times and then analyzed by an HPLC method to detect oxalate and formate. One
unit of
activity is defined as the amount of enzyme required to produce 1 mole of
formate from
oxalate under the above conditions within one minute.
[079] OxOx activity was also measured by monitoring hydrogen peroxide
production
through a horseradish peroxidase catalyzed color reaction: 10 gl of liquid
sample or solid
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
24
suspension was incubated with 990 l of 2 mole of oxalate, 0.3 mg of 1, 4-
amino antipyrine,
3.0 mg phenol and five units of peroxidase in 50 mM phosphate buffer, pH 7.0,
at 37 C for 5
min. After five minutes the absorbance at 510 nm was measured along with the
control. One
unit of activity is defined as the amount of enzyme required to produce 1.0
mole of
hydrogen peroxide under the above conditions.
[080] Stability in Simulated Gastric Fluid (SGF): SGF was prepared according
to the USP
(United States Pharmacopeia) method: 2 g of NaCl, 7 ml of concentrated HCl,
and 3.2 g of
pepsin, filled with water to 1 liter. Sample suspensions were treated with
SGF: 0.4 mL of
sample mixed with 0.6 mL of SGF at 37 C and mixed for 10 min, then
neutralized with 0.1
mL of 500 mM NaOH. The suspension was centrifuged to remove supernatant and
the pellet
was immediately tested for activity as described previously. For solution
samples treated with
SGF: 0.4 mL of sample was mixed with 0.6 mL of SGF and incubated at 37 C for
10 min,
then neutralized with 500 mM NaOH and immediately tested for activity as
described
previously.
[081] Stability in Simulated Intestinal Fluid (SIF): SIF was prepared
according to USP
(United States Pharmacopeia): 6.8 g of monobasic potassium phosphate in 250 mL
of water,
mix, and add 77 mL of 0.2 N sodium hydroxide and 500 mL of water. Add 10.0 g
of
pancreatin, mix, and adjust the resulting solution with either 0.2 N sodium
hydroxide or 0.2 N
hydrochloric acid to a pH of 6.8 0.1. Dilute with water to 1000 mL. Sample
suspensions
were treated with SIF: 0.4 ml of sample mixed with 0.6 ml of SIF at 37 C and
shaked for 10
min, then neutralized with 0.1 ml of 500 mM NaOH. The suspension was
centrifuged to
remove supernatant and the pellet was immediately tested for activity as
described
previously. For solution sample treated with SIF: 0.4 ml of sample was mixed
with 0.6 ml of
SIF and incubated at 37 C for 10 min, then neutralized with 500 mM NaOH and
immediately tested for activity as described previously.
[082] Thermal Stability: To demonstrate thermal stability, suspended pellets
or solution
samples were incubated at 50-85 C in 5 C intervals for 10 min, and then
immediately
cooled on ice. The treated samples were tested for activity as described
previously.
[083] Enzyme functional pH range: Samples were assayed as described earlier
except that a
series of buffers within a pH range of 1.9-8.0 were used. These buffers were
composed of 50
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
mM citrate buffer for pH 2.0-5.5, or 50 mM phosphate buffer for pH 6.0, 6.5,
7.0, 7.5 and
8Ø
Example 2: OxDC activity in mushrooms
[084] Mushrooms collected from nature were identified and those purchased from
supermarkets were translated to their Latin names. These mushrooms were
cleaned and
homogenized in the presence of deionized (DI) water. The homogenized samples
were
separated into supernatant and pellet fractions by centrifugation and both
fractions were
tested for oxalate-degrading activity. To determine specific activity/gram of
dry weight, 10-
15 grams of each pre-weighed strain of mushroom were dried at approximately 60
C to a
constant weight. The pellet fractions were further washed with water with a
dilution factor of
1:50, then re-suspended in water for testing the pH activity profile,
stability in SGF, and
thermal stability.
[085] Approximately 100 different species of mushrooms were tested under this
invention
as showed in Table 2, and 77 of them exhibited oxalate-degrading activity
greater than 0.5
unit per gram of dried mushroom material. In most cases, the oxalate degrading
activity was
associated to OxDC activity, because an equal mole amount of formate was
detected.
Considering that the oxalate degrading activity from these mushrooms could be
affected by
the age of the mushroom, growth conditions, and handling process, the number
of
mushrooms that may produce oxalate-degrading enzyme during their life cycle,
may be even
more. However, majority of the mushrooms showed OxDC activity, indicating that
this
enzyme is a common enzyme amongst fungi.
Table 2. OxDC Activity from Select Fungi
Names Activity (u/g dry material)
Dentinum repandum 4
Amanita solitarii-formis 0
Suillur birfellur 0
Russula virescens 2
Amanita raelon is ora 0
Armillaria tabescens 3.6
Cantharellur cinnabarinur 0.4
Boletur rubellus var fraternus 1.5
Collybia acervata 0.3
Crepidotus mollis 3.5
Boletur sub labri es 0.2
Boletus ornatipes 2.3
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
26
Names Activity (u/g dry material)
Le iota rachodes 0
Polyporus elegans 3.1
Agricus bisporus 0
Pluteus cervinus 3.8
Agricus bisporus 0
Scleroderma citrinum 3.8
Pleurotus ostreatus 0.6
Xerula radicata 5
Thelephora vlalis 3.3
Clitocybe 0.4
Cortinarius cedretorun 1.8
Russula amoenolens 0
Lactarius indigo 3.9
H o horus chrysodon 0
Russula ematica fined 0
Cantharellus cibarius 0
Lactarius tomentosu 0
Pleorotus 0
Russula densi olia 2.6
Amanita rho alo us 3
Gymnopilus 0
Clitocybe hydrograma 1
Hypholoma 0
Lactarius luteolus 0
Marasmius rotula 0
Amanita vaginata 0
Amanita gemmata 3.3
Amanita pachycolia 0
Cortinarius lewisii 2.7
Cortinarius delibutus 0
Pleurotus e n ii 4.3
Inocybe rimosa 5.5
Lactarius atrorividus 3.6
Lepiota cristata 0
Nolanea verna 0
Plutus australis 0
Russula cyanoxhanth 0.9
Scleroderma polyrhizum 3.6
Lentinula edodes 1
Lentinula edodes 1.5
Hy si us tessellatus 3.4
Flammulina velutipes 4.4
Morchella esculenta 0
Leucangia carthusiana 20
Tuber oregonense 12
Gri ola ondosa 0.7
Tremellodendropsis semivestitum 0
Strobilom ces confusus 0
Mutinus Caninus 0
Austroboletus subflavidus 0
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
27
Names Activity (u/g dry material)
Austroboletus gracilis 0
Boletus rubricitrinus 2.1
Boletus pallidus 0
Boletus subglabripes 0
T to ilus conicus 0
Boletusfairchildianus 0
Boletus aternus 1.1
G ro orus subalbellus 0.6
Leucoagaricus americanus 1.2
Omphalotus olearius 3.9
Coprinus disseminatus 0.6
Suillus cothurnata 0
Xeromphalina campanella 0
Amanita brunnescens 1
Russula helero h lla 0.2
Mycorrhaphium adustum 2.4
Armillaria tabescense 2.9
Amanita as era 0
Pleurotus ostreatus 0
Russula mariae 0
Pleurotus ostreatus 2nd 0
Agaricus blazei 0
Boletus flaviporus 0.9
Russula pectintoides 0.6
Lentinula boryana 0.3
Amanita mutabilis 1.6
G ro orus subalbellus 2nd 2.5
Coll bia peronata 2.9
Lactarius corrugis 1.2
Rhodos be 1.3
Macros be titaus 1.2
Hydnum repandum 0
Collybia 0.9
Pluteus 0.3
Lactarius yazooensis 1.3
Leccinum insigne 0.4
Psathyrella candolleana 0
Coprinus comatus I
Polyporus tuberaster 2.3
A oc be aegerita 3.5
Trametes versicolor 2.7
Ganoderma lucidum 2
H si us ulmarius 4
Lentinula edodes (warm) 1.2
Lentinula edodes (cold) 1.7
Lentinula edodes (wide range) 2
Stropharia rugoso-annulatat n/a=0
Hericuium erinaceus 0
Laetiporus coni ericola 0
Pholiota nameko 0
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
28
Example 3: OxOx activity in mushrooms
[086] Samples tested in Example 2 which showed little to no formate production
as
compared to oxalate degraded were further tested for production of hydrogen
peroxide to
determine the presence of OxOx activity. OxOx activity was detected from 3
mushrooms:
Russula amoenolens, Lactarius tomentosu and Agaricus blazei in the contents
with 1.2, 4.7
and 2.1 units per gram of dried mushrooms, respectively.
Example 4: Production of OxDC by fermentation
[087] Mushroom fungi cultured by fermentation are listed in Table 3. Cultures
were grown
on malt agar plates containing (w/v): 3% malt extract, 0.5% soy peptone, and
1.5% agar, and
maintained at 4 C. All fungi were cultivated in malt extract liquid culture
medium (pH 6.0)
containing (w/v): 2.0% glucose, 0.2% (w/v) yeast extract, 2% malt extract,
0.1% KH2PO4,
0.03% Na2HPO4.2H2O, and 0.05% MgSO4.7H2O. The medium was autoclaved at 121 C
for
20 min. Cultivation and production of OxDC was performed in 1.0 L flasks
containing 250
mL of liquid medium and cultured at 25 C for 10-20 days to reach
Table 3. Production of OxDC from Select Fungi by Fermentation
Names Activity (U/g)
Induction H
Gri ola ondosa 0.7 3
Co rinus comatus 18 3.2
Polyporus tuberaster 8.2 3
A roc be aegerita 20 3
Trametes versicolor 7.1 2.5
Ganoderma lucidum 5.6 2.5
H si us ulmarius 14 3.2
Lentinula edodes (warm) 4.5 2.8
Lentinula edodes (cold) 6.7 2.8
Lentinula edodes (wide range) 5.2 2.8
Flammulina velutipes 15 3
Siro haria ru oso-annulata n/a=0 0
Hericium erinaceus 0 0
Laetiporus conifericola 0 0
Pholiota nameko 0 0
10-30 g of wet mycelia per liter of culture. Then 1.0 M sulfuric acid, or 1.3
M phosphoric
acid was added to adjust the pH to 2.0-3.5, and induce OxDC production. The pH
was
maintained by checking every 2 hours and adjusted by adding any of the above
acid
solutions. The actual induction pHs for these fungi are listed in Table 3.
After 3 days of
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
29
induction, mycelia were harvested by centrifugation and re-suspended in water.
The mycelia
suspension was homogenized and centrifuged. The supernatant and pellet both
were
collected. The supernatant was directly tested for OxDC activity. The
supernatants usually
contained 5-15% of the total OxDC activity and were not used for further
testing. The pellet
was washed with water in a 1:50 dilution factor and then re-suspended for
testing OxDC
activity. OxDC activity from these pellet suspensions are given in Table 3.
Example 5: Production of OxOx by plants
[088] Barley or wheat seeds supported by stainless steel mesh were half
emerged in water
for germination and growth at room temperature. After 10-12 days, the young
plants were
harvested and cut into small pieces for homogenization. The homogenized sample
was
centrifuged. The supernatant and pellet both were collected and tested for
OxOx activity.
[089] 100 grams of fresh leafs from Bougainvillea buganvilla and 50 grams of
ten day old
Sorghum vulgaris plants were homogenized separately in cold deionized (DI)
water. The
homogenized samples were passed over a 200-micron sieve and then separated
into
supernatant and pellet fractions by centrifugation at 3500 g for 10 minutes.
The pellet was re-
suspended in water and both fractions were tested for oxalate-degrading
activity. To
determine specific activity/gram of dry pellet weight, pellet from 10 mL of
suspension was
collected by centrifugation at 3500 g for 30 minutes and then dried at
approximately 60 C to
a constant weight.
[090] OxOx from both Barley and wheat is stable and active in acid pH within a
range of
2.0-5.5, but OxOx from Bougainvillea buganvilla leaves is stable and active
around neutral
pH with a range of 5.5-8Ø
Example 6: Demonstration of enzyme stability in simulated gastric fluid
[091] OxDC from mushrooms or fermented mycelia and OxOx from mushrooms were
treated with SGF to simulate the harshest condition in the human stomach as
described in
Example 1. The mushrooms or mycelia that retained OxDC or OxOx activity after
SGF
treatment are given in Table 4.
Table 4. OxDC and OxOx Remaining Activity from Select Fungi after SGF
treatment
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
Names Remaining Activity
Dentinum repandum 101
Russula virescens 109
Boletur rubellus var aternus 87
Crepidotus mollis 64
Polyporus elegans 89
Scleroderma citrinum 108
Xerula radicata 97
Thelephora vlalis 105
Lactarius indigo 102
Russula densi olia 113
Inocybe rimosa 94
Lactarius atrorividus 93
Scleroderma polyrhizum 111
Lentinula edodes 92
Lentinula edodes 93
Flammulina velutipes 92
Omphalotus olearius 96
M corrha hium adustum 89
Armillaria tabescense 47
Russula pectintoides 68
Lactarius yazooensis 88
Leccinum insigne 65
Polyporus tuberaster 67
A oc be aegerita 96
Trametes versicolor 99
Ganoderma lucidum 103
Lentinula edodes (warm) 93
Lentinula edodes (cold) 90
Lentinula edodes (wide range) 91
Agaricus blazei (OxOx) 91
Lactarius tomentosu (OxOx) 91
Example 7: Enzymes that are active in the entire pH range the human stomach
can experience
[092] OxDC from mushrooms or fermented mycelia and OxOx from mushrooms and
plants
were tested for oxalate degrading activity from pH 1.9-5.5. Several of these
enzyme
preparations were even tested for activity up to pH 7.5, as described in
Example 1. The
results are given in Table 5. The optimum pH range is defined by an enzyme
with at least
40% of its highest activity at any pH within the range and the active pH range
is defined as
showing at least 5% of its highest activity at any pH within the range. Many
of these enzymes
are active from pH 1.9-5.3 or even broader pH 1.9-6.3, thus covering the
entire pH range that
the human stomach can experience. It should be noted that enzyme activity at
pH lower than
1.9 was not examined, but it is reasonable to assume that some of these
enzymes should be
active at pH lower than 1.9, which show an optimum activity at pH 1.9.
Table 5. Optimum and Active PH Ranges of OxDC or OxOx from Select Fungi
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
31
Names Optimum pH range Active pH range
Dentinum repandum 1.9-3.2 1.9-4.3
Russula virescens 1.9-2.7 1.9-4.3
Boletur rubellus var aternus 1.9-3.2 1.9-4.3
Cre idotus mollis 3.2-4.3 1.9-5.3
Polyporus elegans 1.9-2.7 1.9-3.2
Scleroderma citrinum 1.9-3.2 1.9-5.3
Xerula radicata 2.7-3.2 1.9-5.3
Thele Nora vlalis 1.9-2.7 1.9-4.8
Lactarius indigo 1.9-3.2 1.9-4.3
Russula densi olia 1.9-3.2 1.9-4.3
Pleurotus e n ii 3.5-4.5 3.2-5.3
Inocybe rimosa 2.7-3.2 1.9-4.8
Lactarius atrorividus 1.9-3.2 1.9-4.3
Sderoderma polyrhizum 1.9-3.2 1.9-4.3
Lentinula edodes 2.5-3.0 1.9-5.5
H si us tessellatus 3.5-4.0 2.5-5.5
Flammulina velutipes 2.7-4.0 1.9-5.5
Leucangia carthusiana 2.7-4.0 1.9-5.5
Tuber oregonense 2.7-4.0 1.9-5.5
Gri ola ondosa 2.7-3.2 1.9-3.2
Boletus rubricitrinus 1.9-2.7 1.9-3.2
Boletus aternus 1.9-3.2 1.9-5.3
G ro orus subalbellus 1.9-3.2 1.9-5.3
Leucoagaricus americanus 1.9-3.2 1.9-4.3
Omphalotus olearius 1.9-4.3 1.9-5.3
Coprinus disseminates 2.7-3.2 1.9-4.3
Amanita brunnescens 2.7-3.2 1.9-4.3
M corrha hium adustum 1.9-2.7 1.9-4.3
Armillaria tabescense 2.7-3.2 1.9-4.3
Boletus avi onus 2.7-5.3 1.9-6.3
Russula pectintoides 1.9-4.3 1.9-5.3
Amanita mutabilis 2.7-3.2 1.9-5.3
G ro orus subalbellus 2" 1.9-3.2 1.9-5.3
Coll bia eronata 1.9-3.2 1.9-4.3
Rhodos be 1.9-3.2 1.9-4.3
Macros be titaus 2.7-3.2 1.9-4.3
Lactarius yazooensi 2.7-4.3 1.9-5.3
Leccinum insigne 2.7-3.2 1.9-4.8
Coprinus comatus 3.2-6.0 1.9-6.3
Polyporus tuberaster 1.9-3.2 1.9-4.8
A roc be aegerita 2.7-3.7 1.9-6.3
Trametes versicolor 1.9-2.3 1.9-4.3
Ganoderma lucidum 1.9-2.7 1.9-4.5
Lentinula edodes (warm) 2.5-3.0 1.9-5.5
Lentinula edodes (cold) 2.5-3.0 1.9-5.5
Lentinula edodes (wide range) 2.5-3.0 1.9-5.5
Agaricus blazei (OxOx) 2.5-3.0 1.9-4.8
Lactarius tomentosu (OxOx 2.5-3.0 1.9-4.3
[093] As shown in Figure 1, OxDC from three selected mushrooms show
significantly
different pH activity profiles. OxDC from L. edodes shows activity at pH 2.0-
5.0 with
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
32
optimum activity at pH 2.5-3.0, while OxDC from F. velutipes shows activity at
pH 2.5-5.0
with optimum activity at pH 3.0-3.5. Furthermore, OxDC from H. tessellatus
reveals activity
at pH 3.0-5.0 with optimum activity at pH 3.5-4Ø
Example 8: Thermal stability
[094] OxDC from mushrooms or fermented mycelia and OxOx from mushrooms were
heat
treated from 50 to 80 C as described in Example 1. The temperatures that
retained more
than 70% of the original OxDC or OxOx activity are given in Table 6.
Table 6. Thermal stability of OxDC and OxOx from Select Fungi
Names Temperature ( C)
Scleroderma citrinum >80
Flammulina velutipes 75
Omphalotus olearius 75
Boletus avi onus 65
Russula pectintoides 75
Lactarius azooensis 70
Coprinus comatus 75
A roc be aegerita 75
Agaricus blazei (OxOx) 70
[095] As shown in Figure 2, OxDC from L. edodes was determined to be thermally
stable at
55 C, lower than OxDC from H. tessellates and F. velutipes, which both were
stable up to 70
C, respectively.
Example 9: Degradation of food oxalate in simulated gastric conditions
[096] Food mixtures were produced by mixing and homogenizing (w/w): 5%
spinach, 15%
cooked chicken, 40% cooked rice and 40% water. The total oxalate content was
90 mg per
100 g of this food mixture. The average daily oxalate intake from Western
diets is 50-250
mg. Three conditions were evaluated to simulate snacks and full meals. The
testing
experiments were scaled down five times from the actual average amount of
stomach juice
(150 mL).
[097] The food mixture was mixed with simulated gastric fluid: 10, 40 and 200
g of food
mixture was mixed with 30 ml of simulated gastric fluid (84 mM HCl with 3.2
mg/ml pepsin)
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
33
and then filled with water to 40, 160 and 800 g, respectively. A homogenized
mycelia
suspension, which was made from fermentation of Agrocybe aegerita and
contained
approximately 15 units of oxalate decarboxylase per gram of suspension or 150
units per
gram of dried mycelia powder, was used to degrade oxalate from these food
mixtures. 5, 20
and 100 g of the homogenized mycelia suspensions were added to these food
mixtures,
respectively. The final pH of the three reaction mixtures was 2.3, 3.4 and
5.2. The mixtures
were mixed slowly and maintained at 37 C. Samples were taken at 0, 5, 10, 20,
30, and 40
minutes for soluble oxalate determination. Soluble oxalate was measured by an
HPLC
method as described in Example 1 for the oxalate decarboxylase activity assay.
The soluble
oxalate concentrations dropped from 0.82, 0.66 and 0.43 mM for the three cases
from small
size to large size food mixtures, respectively, to less than 0.1 mM in 10
minutes and further
dropped to less than 0.03 mM for all three cases after 40 minutes.
Example 10:
[098] Functional pH shift from pH 6.5 to 7.0 by immobilization 20 mg of crude
enzyme was
obtained from the cultured fungi homogenized supernatant, which contained 10
Units/mg of protein.
The crude enzyme was mixed with 1% of chitosan solution (>92% deacetylation)
at pH 4.0, then
0.3% tripolyphosphate (TPP) solution was added until most of the chitosan
formed particles. The
particles were collected by centrifugation at 2000 g for 10 minutes and re-
suspended in water.
Glutaraldehyde was added to a final concentration of 1% with pH adjusted to pH
8.0 with 1 N
NaOH. The cross-linking reaction was for 10 minutes at 25 C and was then
diluted 10 times with
water. The cross-linked particles were immediately washed with water at a
dilution rate of 1000 to
remove most free glutaraldehyde and the washed particles were used for the
functional pH assay and
the activity results shown in Figure 4.
[099] Identification of the fungal species found in the culture collections
can be obtained from
Table 7 by the accession numbers provided.
Table 7. Fungal Species Found in Culture Collections
Names Accession Numbers
Dentinum repandum PSU 558
Amanita solitarii-formis ATCC 26842
Suillus birfellur
Russula virescens FMRC SO 16
Amanita praelongispora BPI 750680
Armillaria tabescens ATCC 62415
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
34
Names Accession Numbers
Cantharellus cinnabarinus FMRC S02021
Boletus rubellus var aternus BPI 781712
Collybia acervata BPI 1102144
Crepidotus mollis ATCC 96569
Boletus sub labri es BPI 781892
Boletus ornatipes BPI 781195
Le iota rhacodes NCIM 1155
Pol onus ele ans BPI 1113147
Agaricus bisporus FGSC 10389
Pluteus cervinus PSU 571
Agaricus bisporus FGSC 10389
Scleroderma citrinum UU F-149335
Pleurotus ostreatus PSU 610
Xerula radicata BPI 769566
Thelephora vial is CGMCC 550*
Clitocybe aurantiaca PSU 3
Cortinarius cedretorum BPI 774972
Russula amoenolens CBS 133*
Lactarius indigo BPI 759669
H ro horus chrysodon BPI 1104446
Russula ematica fined FMRC SO 15
Cantharellus cibarius PSU 560
Lactarius torminosus BPI 763347
Pleorotus herbrodensis PSU 850
Russula densi olia CBS 133*
Amanita rho alo us LSID 308584
Gymnopilus spectabilis FMRC S048
Clitocybe hydrogramma BCRC 59*
Hypholoma dispersum PSU 69
Lactarius luteolus PSU W59
Marasmius rotula ATCC 62251
Amanita va inata FMRC S004
Amanita gemmata FMRC S00121
Amanitapachycolea LSID 109592
Cortinarius lewisii LSID 360163
Cortinarius delibutus CCBAS 558*
Pleurotus eryngii ATCC 36047
Inocybe rimosa CBS 210.55
Lactarius atroviridis LSID 226377
Lepiota cristatiformis BPI 751892
Nolanea verna LSID 283581
Pluteus australis LSID 441053
Russula cyanoxhanth CBS 133*
Scleroderma of rhizum BPI 711197
Lentinula edodes ATCC 28759
Lentinula edodes ATCC 38222
Hypsizygus tessellatus FMRC SO 13122
Flammulina velutipes FP LCTTFV
Morchella esculenta PSU 744
Leucangium carthusianum LSID 169340
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
Names Accession Numbers
Tuber oregonense LSID 515123
Gri ola ondosa ATCC 11936
Tremellodendropsis semivestita LSID 169340
Strobilomyces confusus LSID 515123
Mutinus Caninus PSU 182
Austroboletus subflavidus LSID 118437
Austroboletus gracilis LSID 118431
Boletus rubricitrinus BPI 781645
Boletus pallidus BPI 781208
Boletus subglabripes BPI 781892
T to ilus conicus BPI 782426
Boletusfairchildianus LSID 309677
Boletus aternus BPI 780755
Gyro onus subalbellus BPI 782362
Leucoagaricus americanus LSID 466261
Omphalotus olearius PSU W35
Coprinus disseminatus ATCC 46973
Suillus cothurnatus CBS 213.76
Xerom halina campanella CBS 507.48
Amanita brunnescens BPI 750090
Russula hetero h lla BPI 764312
Mycorrhaphium adustum BPI 348302
Armillaria tabescense BPI 747151
Amanita as era BPI 750101
Pleurotus ostreatus PSU 628
Russula mariae BPI 764415
Pleurotus ostreatus 2nd PSU 598
Agaricus blazei ATCC 76739
Boletus flaviporus BPI 780557
Russula ectinatoides BPI 764603
Lentinula bo ana PSU 787
Amanita mutabilis ATCC 26846
G ro orus subalbellus 2nd BPI 782362
Collybia eronata ATCC 62243
Lactarius corrugis PSU W58
Rhodocybe roseoavellanea BPI 771252
Macrocybe titans LSID 443595
H dnum re andum BPI 1102039
Collybia dr o hila ATCC 62269
Pluteus cervinus PSU 571
Lactarius yazooensis LSID 116133
Leccinum insigne LSID 333018
Psathyrella candolleana PSU 32
Coprinus comatus ATCC 12640
Polyporus tuberaster CBS 786.84
A roc be aegerita ATCC 3645
Trametes versicolor ATCC 11235
Ganoderma lucidum ATCC 32471
H si us ulmarius PSU 412
Lentinula edodes (warm) PSU 376
CA 027817122012-0523
WO 2011/066282 PCT/US2010/057805
36
Names Accession Numbers
Lentinula edodes (cold) PSU 375
Lentinula edodes (wide range) PSU 878
Stropharia rugoso-annulatat PSU 406
Hericuium erinaceus PSU 27
Laetiporus coni ericola LSID 372852
Pholiota nameko ATCC 42261
BPI = USDA Agriculture Research Service Fungal Database
ATCC = American Tissue Culture Collection
PSU = Penn State University Mushroom Collection Center
FMRC = Florida Mycology Research Center
FGSC = Fungal Genetic Stock Center
FP = FungiPerfecti
UU = Uppsala University Botany Section
UA = University of Alberta Microfungus Collection
CGMCC = China General Microbiological Culture Collection Center
CCBAS = Culture Collection of Basidiomycetes
CBS = Centraalburea voor Schimmelcultures, Fungal and Yeast Collection
LSID = Index Fungorum
NCIM = National Collection of Industrial Microogranisms
BCRC = Bioresource Collection and Research Center
*These fungal species are found within these databases; however, no accession
numbers are assigned.
